Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 222 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diastole Clear all
Completed Phase 3 Interventional

A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.

NCT00171366
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,422 participants
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

NCT01052428
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
metoprolol succinate (Toprol XL), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 22, 2026, 10:33 PM EDT
Withdrawn Phase 2 Interventional

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

NCT07221513
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions
JK07
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

NCT00362115
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
46
States / cities
Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 4 Interventional

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

NCT00170924
View directory record Official record
Conditions
Diastolic Dysfunction, Hypertension
Interventions
Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years and older
Enrollment
317 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 22, 2026, 10:33 PM EDT
Not yet recruiting Not applicable Interventional

Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)

NCT07756398
View directory record Official record
Conditions
Valvular Heart Disease Patients, Aortic Stenosis, Mitral Regurgitation, Left Ventricular Diastolic Dysfunction
Interventions
Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years to 85 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Results available

PIE II: Pharmacological Intervention in the Elderly II

NCT00123955
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure, Congestive
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 22, 2026, 10:33 PM EDT
Terminated Not applicable Interventional

Muscle, Essential Amino Acids, and eXercise in Heart Failure

NCT03312387
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Exercise, Essential Amino Acids, Placebo
Other · Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 22, 2026, 10:33 PM EDT
Recruiting Phase 4 Interventional

A Preliminary Study for INFORMED

NCT05585125
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Not applicable Interventional

A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure

NCT02084992
View directory record Official record
Conditions
Congestive Heart Failure, Diastolic Heart Failure, Systolic Heart Failure
Interventions
Expanded technology disease management, Telephonic disease management
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Framingham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction

NCT01901809
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Furosemide, Dopamine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Results available

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

NCT02251431
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions
BYDUREON, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 10:33 PM EDT
Active, not recruiting Phase 2 Interventional

Study of JK07 in Patients With Chronic Heart Failure

NCT06369298
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
JK07, Placebo
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
51
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects

NCT02874703
View directory record Official record
Conditions
HIV, Diastolic Dysfunction, Myocardial Fibrosis
Interventions
Cardiac MRI/MRS
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

NCT00853957
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)

NCT02058095
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Inflammation to Treat Cardiovascular Aging

NCT01775865
View directory record Official record
Conditions
Vascular Stiffness, Endothelial Dysfunction, Diastolic Dysfunction
Interventions
Salsalate, Placebo (for salsalate)
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
18 Years to 79 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 22, 2026, 10:33 PM EDT
Withdrawn Phase 4 Interventional

L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD

NCT01855334
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Spironolactone, L-arginine, Placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Not applicable Interventional

Resistance Training in HFpEF

NCT02435667
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction
Interventions
Resistance Exercise Training, DEXA bone scan, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, Submaximal Exercise Test, Blood Draw
Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 10:33 PM EDT
Completed No phase listed Observational

The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

NCT02275793
View directory record Official record
Conditions
Diastolic Heart Failure, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 22, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

Physiological Effects of Grape Seed Extract in Diastolic Heart Failure

NCT01185067
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
Interventions
grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 22, 2026, 10:33 PM EDT
Recruiting No phase listed Observational

Pediatric Cardiomyopathy Mutation Analysis

NCT02432092
View directory record Official record
Conditions
Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 10:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

Assessment of CCM in HF With Higher Ejection Fraction

NCT05064709
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
105
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 10:33 PM EDT